Wall Street brokerages forecast that Kamada Ltd. (NASDAQ:KMDA) will post $25.99 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Kamada’s earnings, with estimates ranging from $24.07 million to $27.90 million. Kamada posted sales of $22.92 million in the same quarter last year, which would indicate a positive year over year growth rate of 13.4%. The company is scheduled to report its next earnings results on Monday, November 12th.
According to Zacks, analysts expect that Kamada will report full year sales of $111.52 million for the current year, with estimates ranging from $105.00 million to $118.80 million. For the next year, analysts expect that the firm will report sales of $147.76 million, with estimates ranging from $128.20 million to $177.68 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Kamada.
Kamada (NASDAQ:KMDA) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.09 by $0.05. The business had revenue of $33.84 million during the quarter, compared to analyst estimates of $29.64 million. Kamada had a return on equity of 14.43% and a net margin of 11.79%.
A number of research analysts have weighed in on the company. Zacks Investment Research raised Kamada from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a report on Friday, August 10th. BidaskClub raised Kamada from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. ValuEngine raised Kamada from a “sell” rating to a “hold” rating in a report on Monday, July 30th. Finally, HC Wainwright set a $11.00 target price on Kamada and gave the company a “buy” rating in a report on Wednesday, August 8th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Kamada presently has a consensus rating of “Buy” and a consensus price target of $8.08.
Several hedge funds and other institutional investors have recently modified their holdings of KMDA. Acadian Asset Management LLC grew its holdings in shares of Kamada by 157.8% during the second quarter. Acadian Asset Management LLC now owns 292,795 shares of the biotechnology company’s stock worth $1,507,000 after purchasing an additional 179,237 shares in the last quarter. ARK Investment Management LLC grew its holdings in shares of Kamada by 14.8% during the second quarter. ARK Investment Management LLC now owns 119,537 shares of the biotechnology company’s stock worth $616,000 after purchasing an additional 15,440 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Kamada by 8.1% during the second quarter. Renaissance Technologies LLC now owns 464,900 shares of the biotechnology company’s stock worth $2,417,000 after purchasing an additional 34,800 shares in the last quarter. Macquarie Group Ltd. grew its holdings in shares of Kamada by 71.7% during the second quarter. Macquarie Group Ltd. now owns 47,547 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 19,851 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Kamada during the second quarter worth about $146,000. 11.26% of the stock is owned by institutional investors.
KMDA stock traded down $0.10 during mid-day trading on Wednesday, reaching $5.34. 228 shares of the company traded hands, compared to its average volume of 7,307. The company has a quick ratio of 2.85, a current ratio of 3.95 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $219.79 million, a PE ratio of 29.67 and a beta of 1.34. Kamada has a 52-week low of $4.26 and a 52-week high of $6.45.
Kamada Company Profile
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD).
Featured Article: What Factors Can Affect Return on Equity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.